• Penumbra, Inc. recently initiated a voluntary Class II recall of its Penumbra System RED 68 Reperfusion Catheter across multiple US states and international markets due to manufacturing issues that may cause catheter fractures, following firm notifications sent out in early June 2026.
• This recall comes shortly after Penumbra reported higher quarterly sales of US$390.05 million but lower net income of US$34.81 million and reduced earnings per share versus a year earlier, highlighting growing quality-control and profitability pressures at the same time.
• We will now examine how the recent RED 68 catheter recall could influence Penumbra's previously optimistic growth and margin-focused investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Penumbra Investment Narrative Recap

To own Penumbra, you have to believe in long term growth in minimally invasive stroke and vascular interventions, supported by strong clinical data and new devices. In the near term, the key catalyst is wider adoption of its thrombectomy platforms, while the biggest risk is product quality and regulatory scrutiny. The RED 68 Class II recall speaks directly to that risk, but it currently appears limited to specific lots rather than the whole RED family.

The most relevant recent announcement is Penumbra’s second quarter 2026 earnings, where sales rose to US$390.05 million while net income fell to US$34.81 million. That mix of higher revenue and lower profitability already pointed to margin pressure, and the RED 68 recall adds another layer of potential cost and operational complexity just as Penumbra pushes major launches like Thunderbolt within its neurovascular thrombectomy franchise.

Yet behind the growth story, investors should also be aware of how a device recall can influence hospital trust, regulatory attention, and future trial driven adoption...

Penumbra's narrative projects $2.1 billion revenue and $311.7 million earnings by 2029. This requires 12.7% yearly revenue growth and about a $140.7 million earnings increase from $171.0 million today.

Uncover how Penumbra's forecasts yield a $363.36 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Before this recall, the most cautious analysts already saw slower progress, with revenue only reaching about US$2.0 billion and earnings US$275.0 million by 2029, so this kind of quality issue could reinforce their concerns about Thunderbolt and related next generation platforms.

Explore 2 other fair value estimates on Penumbra - why the stock might be worth as much as 11% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Penumbra research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Penumbra research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Penumbra's overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.